Cat. No. 1813
Alternative Name: Indirubin-3'-monoxime
Chemical Name: 3-[1,3-Dihydro-3-(hydroxyimino)-2H-
Biological ActivityProtein kinase inhibitor; inhibits cyclin-dependent kinases (IC50 = 0.18 - 3.33 μM) and GSK-3β (IC50 = 0.19 μM). Inhibits CDK5- and GSK-3β-mediated tau phosphorylation, a process over-active in Alzheimer disease states. Also inhibits AMPK, LCK and SGK. Induces cell cycle arrest and inhibits cell proliferation.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Bain et al (2003) The specificities of protein kinase inhibitors: an update. Biochem.J. 371 199. PMID: 12534346.
Leclerc et al (2001) Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. J.Biol.Chem. 276 251. PMID: 11013232.
Hoessel et al (1999) Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat.Cell.Biol. 1 60. PMID: 10559866.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Indirubin-3'-oxime from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Indirubin-3'-oxime, supplier, Protein, kinase, GSK-3β, GSK-3beta, inhibits, inhibitors, kinases, Cyclin-dependent, Induces, cell, cycle, arrest, antiproliferative, Broad, Spectrum, GSK, Glycogen, Synthase, 3, Cdk, Cyclin-Dependent, Carbohydrate, Metabolism, Cell, Cycle, Indirubin-3-oxime, Indirubin-3-monoxime, Tocris Bioscience, Glycogen Synthase Kinase 3 Inhibitor products
Find multiple products by catalog number
New Products in this Area
Selective non-ATP competitive inhibitor of GSK 3βBI 605906
Selective IKKβ inhibitorGSK 319347A
Potent and selective IKKε inhibitorFRAX 597
Potent group I PAK inhibitorMRT 68921 dihydrochloride
Potent ULK inhibitor; inhibits autophagyAM 2394
Potent glucokinase activator; orally bioavailableeCF 309
Potent mTOR inhibitorPF 3758309 dihydrochloride
Potent PAK4 inhibitor; orally availableAZ Dyrk1B 33
Potent and selective Dyrk1B kinase inhibitorPF 06409577
Potent and selective allosteric activator of AMPKPerifosine
PKB/Akt inhibitor; also modulates Kv2.1 currentRAF 265
Raf kinase and VEGFR-2 inhibitorCZC 25146
Potent LRRK2 inhibitorRo 3280
Potent and selective PLK1 inhibitorRMM 46
MSK/RSK family kinase inhibitorLTURM 34
Potent DNA-PK inhibitorMLi-2
Potent and selective LRRK2 inhibitorLTURM 36
PI 3-kinase δ inhibitorPI 3065
Potent and selective PI 3-kinase p110δ inhibitorAZ PFKFB3 67
Potent and selective PFKFB3 inhibitorSTOCK2S 26016
Lysine deficient protein kinase (WNK) signaling inhibitor
April 1 - 5, 2017
Washington, D.C., USA